RegulatoryOfficial

EMA recommends Gazyvaro for adults with active systemic lupus erythematosus, SÚKL reports

🇨🇿 SÚKL · Mon 16 Nov 2026

The EU regulator has backed extending obinutuzumab to moderate-to-severe active SLE as add-on therapy, according to the Czech authority SÚKL; a Commission decision is still to come.

The Czech State Institute for Drug Control (SÚKL) reported on 16 November 2026 that the European Medicines Agency (EMA) has recommended extending the EU use of Gazyvaro (obinutuzumab) to a new indication: systemic lupus erythematosus (SLE).

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Official source: SÚKL ↗

Article written by VigiEye from the official source (SÚKL). AI-assisted; check the source before acting.

More Regulatory All →